Block
DEMO
PAYER, PROVIDERS AND PHARMACIES
HEALTHCARE
PHARMA
We Answer the “What” and the “Why” of
Market Access.
Solutions for Pharmaceutical Manufacturers
Our customers rely on our industry-leading data and insights and cutting-edge technology to overcome barriers to access.
Solutions for
Healthcare IT
Let our unbeatable covered lives methodology and innovative technology inform your market access strategy.
Solutions for Payers, Providers and Pharmacies
Establish reimbursement policies, formulary positioning and access financial assistance that make therapies affordable for patients.
icon-website
Directory of Health Plans
Your source of truth for payer market share. Try out the Directory of Health Plans demo today.
Slide 1
Insights
The 2024 State of Patient Access

MMIT interviewed more than 300 pharma and biotech leaders to learn what keeps them up at night—and what gets them going in the morning. Read on for the survey findings and expert analysis.

Slide 1
Insights
Unleash the Power of Real-World Data

MMIT helps pharma companies harness the power of real world data to better understand the patient journey.

Slide 1
HCP Targeting Report
Find High-Value HCPs for Your Therapy

One of the first steps in your therapy’s commercialization journey should be to identify high-value HCPs who can help guide valuation, messaging and more.

Slide 1
Insights
Intelligent Insights

Our Zitter Insights Panel uses research to illuminate the complexities of market access.

Block
Meet the expert

Strategies for Early Market Access Planning

July 15, 2023 | 1:00pm EDT

As market access challenges grow, pharma companies are beginning their pre-launch planning much earlier in the product lifecycle. According to our research, 33% of pharma companies are now starting their market access planning in Phase I, and 54% by Phase II and III.

Strategies-Early-Market-Access-Planning
07
Days
19
Hours
00
Minutes
13
Seconds
Slide 1

Industry Leading Insights

MMIT offers a range of publications for pharma, payers and providers covering news, strategy and insights across the spectrum. Our in-house journalism division AIS Health provides objective news and analysis of industry trends while RJ Health provides a comprehensive look at industry updates as they apply to medically covered drug reimbursement processes.

Slide 5

"We need doctors to fight the good fight so that any patient who needs the therapy can get the therapy, and MMIT plays a key role in that process. We need you to help us fulfill our mission for our patients."

Vice President of Market Access

Small Pharma Company

Slide 2

"As a small company, we appreciate the flexibility and responsiveness of the MMIT team. Their customer support team has done a great job working with our new hires to get them trained on their solutions."

Mark Devlin

Vice President, Head of Market Access | Phathom Pharmaceuticals

Slide 1

“Ryan [Witherington] and the team at MMIT have been great partners in our initiatives to analyze and communicate payer policy data for our product through innovative field tools, both MMIT-developed and developed by us using MMIT data. FormTrak Web, in particular, has been well-received by our field sales team and we are excited to transition to FormTrak in Veeva to streamline the process and make it an even more valuable tool.”

Director of Market Access

Large Pharma Company

Slide 3

“DHP provided us a list that was stronger than what we typically begin with, which, in turn, lowered the amount of time spent on payer that didn’t fit our profile.”

Erin Studstill

Vice President of Operations and Technology | MarketLauncher

Slide 4

"Throughout my 10 years in market access, I've been exposed to most of the top solutions, at times simultaneously. I've always found myself turning to MMIT because of their products' ease of use and data integrity."

Jai Persico

National Account Executive | Neurocrine Biosciences

previous arrowprevious arrow
previous arrowprevious arrow
next arrownext arrow
next arrownext arrow

Subscribe to MMIT's Thought Leadership

Get the latest from MMIT’s leading subject matter experts, receiving the latest posts right to your inbox. Top-quality thought leadership 100% free.

subscribe today